ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: TH-PO705

Compressed and Concomitant Cyclophosphamide with Prednisone for Membranous Nephropathy: Low Doses for Very-High-Risk Patients

Session Information

Category: Glomerular Diseases

  • 1402 Glomerular Diseases: Clinical, Outcomes, and Trials


  • Silverberg, Benjamin, University of Virginia, Charlottesville, Virginia, United States
  • Cavanaugh, Corey J., University of Virginia, Charlottesville, Virginia, United States

Immunosuppressive therapy for primary membranous nephropathy (MN) has undergone significant change in the last 5 years. The "modified Ponticelli" regimen for MN is the recommended therapy for very high-risk MN according to KDIGO guidelines. The regimen consists of alternating cycles of cyclophosphamide and corticosteroids for a total of 6 months and comes with dose-dependent side effects such as cytopenias, infections, and malignancy. Here, we describe our experience with compressed and concomitant CYC/GC in very high-risk patients.

Case Description

We retrospectively analyzed 4 cases of PLA2R-positive membranous nephropathy with very high-risk features treated with concomitant prednisone 0.5mg/ kg tapered with oral cyclophosphamide 1.5-2mg/kg daily over 3-4 months. All patients were male between the ages 36-62. Clinical data, including serum PLA2R-AB levels and UPCR, were collected over the treatment period and 6 months after completion (Images 1 and 2). All patients had complete or partial remission at 9-12 months follow-up. No cytopenias or infections were observed. One patient developed steroid-related diabetes.


Compared to the 24-week modified Ponticelli regimen, our doses of GC were lower, with a shorter duration of therapy and without any loss in efficacy (Table). A compressed and concomitant CYC/GC regimen in very high-risk patients with PLA2R membranous nephropathy is safe and effective in this limited case series.

 Compressed CYC/Pred Modified Ponticelli (for a 60kg patient)
Average total CYC dose11.21g10.8-13.5g
Average total GC dose1965mg11.4g
Total duration of therapy13.75 weeks24 weeks